CFI and glioma: Collectively, CFI expression is strongly associated with the clinicopathological features of glioma, including PRS type (primary/recurrent/secondary), WHO grade, age, chemotherapy status, IDH mutation status, 1p/19q co-deletion status, and histology grade, and is therefore a promising biomarker for prognosis as well as a therapeutic target.